

Sprint Bioscience presents the VPS34 program at two scientific conferences

In the spring of 2025, Sprint Bioscience will present the VPS34 program at two different conferences: NextGen Biomed 2025 in London, England and the Tumour Models Summit Nordics in Stockholm, Sweden.

The results presented at the NextGen Biomed 2025 conference by Oxford Global in London from March 12-14 demonstrate that inhibition of VPS34 in mice activates the immune system and enhances the treatment response to STING agonists. This discovery opens new possibilities for treatment combinations that could lead to improved therapeutic responses in immunotherapies that rely on the patient's own immune system, such as anti-PD-1/PD-L1 antibodies. The presentation is titled "Improving STING agonist in-vivo efficacy in mice by combination with VPS34 inhibitors."

The presentation at the Tumour Models Summit Nordics in Stockholm from April 9-10 will focus on the tumor models used in the program. This presentation is titled "Using syngeneic models to understand the molecular pathways leading to improved STING therapy using VPS34 inhibitors." At both conferences, Sprint Bioscience will be represented by Santiago Parpal, Principal Scientist, Tumor Biology & Therapeutics.

"We have shown that inhibition of VPS34 can enhance the effect of immune-activating checkpoint inhibitors and STING agonists, which is very promising. The need for improved treatment responses in immuno-oncology is significant, as the effectiveness varies between patients and often diminishes over time. By presenting our previously published results at scientific conferences, we spread the knowledge about our programs and strengthen our already established reputation," says Johan Emilsson, CEO of Sprint Bioscience.

For further information, kindly contact:

Johan Emilsson, CEO, Sprint Bioscience
Tel: +46 (8) 411 44 55
Epost: johan.emilsson@sprintbioscience.com

About Sprint Bioscience AB (publ)

Sprint Bioscience develops small molecule first-in-class drug programs with a focus on oncology. With a fragment-based drug development method, the company develops drug programs in a time- and resource-efficient manner. The programs are out-licensed to global pharmaceutical companies during the pre-clinical phase and the company has successfully entered into several license agreements. The Sprint Bioscience share is listed on the Nasdaq First North Premier Growth Market and trades under the ticker symbol SPRINT. The company is based in Stockholm with operations located in Huddinge. Further information is available on the company's website; www.sprintbioscience.com. Certified Advisor is FNCA Sweden AB, www.fnca.se.

Attachments

[Sprint Bioscience presents the VPS34 program at two scientific conferences](#)